Introduction: The prognosis of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) has been dramatically improved since the introduction of tyrosine kinase inhibitors (TKIs). Although allogeneic hematopoietic cell transplantation (allo-HCT) is a major treatment option, the role of autologous peripheral blood stem cell transplantation (auto-PBSCT) has been reconsidered, especially in patients who achieved early molecular remission.
Introduction
The role of autologous peripheral blood stem cell transplantation (auto-PBSCT) for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) has changed in the era of tyrosine kinase inhibitors (TKIs), although allogeneic hematopoietic cell transplantation (allo-HCT) is still considered to be an option to cure Ph + ALL. [1] [2] [3] [4] [5] In the Cancer and Leukemia Group B (CALGB) 10001 study, overall survival (OS) (median 6.0 years vs not reached) and disease-free survival (DFS) (median 3.5 vs 4.1 years) were similar between patients with a partial or complete molecular response who had undergone autologous transplantation and those who had undergone allo-HCT. [6] In addition, in patients achieving a major molecular response, the outcome was similar between patients who had undergone autologous transplantation and those who had undergone allo-HCT [OS: hazard ratio (HR) 0.94, 95% confidence interval (95% CI) 0.53-1.65, P = .82; DFS: HR 0.95, 95% CI 0.51-1.74, P = .95] in the study of the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). [7] Because hematological complete remission (CR) has been achieved in many patients recently, [8, 9] monitoring of minimal residual disease (MRD) is important for long-term disease control. [10] [11] [12] [13] [14] [15] Age is one of the most important prognostic factors in patients who underwent allo-HCT, although the outcome of allo-HCT is generally favorable in Japan (http://www.jdchct.or.jp/en/data/ slide/2016/). In Ph + ALL patients, an age of 55 years or older has been identified as a risk factor for nonrelapse mortality (NRM) after allo-HCT. [15] On the contrary, the risk of NRM is much lower in auto-PBSCT, and auto-PBSCT has been performed on patients around 70 and up to 75 years old. [16] In this study, we planned to analyze the safety and efficacy of auto-PBSCT for Ph + ALL patients aged between 55 and 70 years with an early molecular response. In addition, immune recovery after auto-PBSCT is also a subject of interest, especially the function of T cells.
Objectives

Primary
The primary endpoint is Day 100-mortality after transplantation.
Secondary
The secondary endpoints are as follows:
(1) Day100-molecular and hematological relapse rate; (2) 1-year molecular and hematological relapse rate; (3) 3-year molecular and hematological relapse rate; (4) Day100-OS, DFS, relapse rate, and NRM; (5) 1-year OS, DFS, relapse rate, and NRM; (6) 3-year OS, DFS, relapse rate, and NRM; (7) The proportion of therapy-related mortality; 3. Methods and analysis
Study design
This is a multicenter exploratory study of auto-PBSCT for Ph + ALL. This study is divided into 3 phases: peripheral blood stem cell harvest (PBSCH), transplantation, and maintenance ( Fig. 1 ).
Because this is an exploratory study, the target sample size is 5, and the registration period is 2 years. This study was registered in the UMIN Clinical Trials Registry with the identifier UMIN000026445.
Study setting
Eight hospitals in Aichi Prefecture agreed to take part in this study: Anjo Kosei Hospital, Ichinomiya Municipal Hospital, Konan Kosei Hospital, Toyohashi Municipal Hospital, Nagoya Medical Center, Japanese Red Cross Nagoya Daiichi Hospital, Japanese Red Cross Nagoya Daini Hospital, and Nagoya University Hospital. The protocol was approved by the institutional review board of each hospital (the latest edition ver. 1.1 13/Jun/2017). Written informed consent was obtained from all patients before registration, in accordance with the Declaration of Helsinki.
Patients are registered in this study after the independent review by the Data center in the Center for Advanced Medicine and Clinical Research of Nagoya University Hospital, where the inclusion and exclusion criteria are checked. Independent monitoring will be planned at least annually according to the Japanese clinical trial guideline.
Participants
The inclusion criteria are as follows: CMR is defined by the absence of detectable MRD with a sensitivity of at least 0.01%. [7] Exclusion criteria are as follows:
1. Heart insufficiency: 1) Uncontrolled angina or heart failure, or myocardial infarction within 3 months. 2) Congenital long QT syndrome. inappropriate for entry into this study. (Fig. 2) . Granulocyte colony-stimulating factor (G-CSF) (filgrastim 400 mg/m 2 or lenograstim 10 mg/kg s.c.) is initiated in the neutropenic phase and continued until the end of PBSCH. PBSCH is initiated on the day when the WBC count is around 5 x 10 9 /L. PBSCH is finished when 2 x 10 6 /kg or more CD34+ cells are collected. The second PBSCH is performed when the total corrected CD34+ cells were less than 2 x 10 6 /kg after 3 days of PBSCH.
Study procedures-PBSCH
The second PBSCH is performed using the CHASE regimen, which is used for PBSCH in lymphoma patients [17, 18] DA 100 mg/day is administered for 14 days or longer from the day following the date of last PBSCH. 
Study procedures-transplantation
The LEED regimen is used as a preparative regimen for autologous PBSCT, which is used for autologous PBSCT in lymphoma patients [17, 19] : melphalan 130 mg/m 2 on Day-1, CPM 60 mg/kg on Days -4 and -3, ETP 500 mg/m 2 on Days -4 to -2, and DEX 40 mg/body on Days -4 to -1 (Fig. 3) . G-CSF (filgrastim 300 mg/m 2 or lenograstim 5 mg/kg s.c.) is initiated on Day 1 and continues until the WBC counts reach around 5 x 10 9 /L.
Study procedures-maintenance
Maintenance therapy is started between Day 30 and Day 50 after transplantation when the patient can undoubtedly take oral medication. As maintenance course #1, DA is initiated as a dose of 50 mg/day, and increased up to 100 mg/day: 50 mg/day on Days1 to 7, 70 mg/day on Days 8 to 14, 100 mg/day on Days 15 to 28, and then ceased on Days 29 to 35. As maintenance course #2-12, a combination of VCR, PSL, and DA is administered: VCR 1.3 mg/m 2 on Day 1, PSL 60 mg/m 2 on Days 1 to 7, and DA 100 mg/day on Days 1 to 28 every 35 days (Fig. 4) .
Minimal residual disease and tumor immunology
In connection with relapse, MRD using RQ-PCR for detection of BCR-ABL chimeric gene and T-cell subsets using flow cytometry, especially FOXP3 + CD25 + CD4 + regulatory T cells (Tregs), [20, 21] are analyzed at designated time points: before conditioning for transplantation, Day 30 after transplantation, before maintenance courses #4, #8, and #12, and 3 years after transplantation.
Discussion
This is an exploratory study for the safety and efficacy of auto-PBSCT for Ph + ALL. It is generally recognized that autologous transplantation has a higher risk of relapse than allogeneic transplantation due to lack of allogeneic immunity but a much lower risk of NRM. Higher age, especially 55 years or older, was reported to be a significant risk factor for NRM after allogeneic transplantation for Ph + ALL. [15] To minimize the risk of NRM and relapse, this study targets patients aged 55 years or older with CMR.
The chemomobilization regimen for PBSCH varies depending on studies. [22, 23] It is common for patients with malignant lymphoma or multiple myeloma to receive high-dose CPM or multidrug chemotherapy and G-CSF. For multidrug chemotherapy, there are several reports using a combination of CPM, anthracycline, and steroids, [24] [25] [26] which are commonly used in combination for Ph + ALL. Therefore, in this study, we chose the Japan Adult Leukemia Study Group (JALSG) Ph + ALL213 consolidation C2 regimen for PBSCH, which was one of widely used chemotherapy regimens for Ph + ALL in Japan (UMIN000012173).
There is no specific preparative regimen of auto-PBSCT for Ph + ALL. Previous studies have used preparative regimens for allogeneic transplantation, or auto-PBSCT for malignant lymphoma or multiple myeloma. [6, 7] In this study, the LEED regimen is used for the following reasons: The regimen is commonly used for auto-PBSCT of malignant lymphoma in participating hospitals; Each drug used in the LEED regimen is covered by insurance in Japan for acute leukemia; and Etoposide has been a key drug of preparative regimen for ALL. [27] [28] [29] Tregs have received a lot of attention in relation to cancer immunity in recent years. Tregs suppress antitumor immunity and contribute to tumor progression and metastasis. [21, 30] On the contrary, in cancer patients, effector cells including CD8 + T cells are primed and expanded to suppress tumors. Therefore, the balance of Tregs and effector T cells will affect the prognosis. In chronic myeloid leukemia patients, it was reported that the number of Tregs was significantly lower in the CMR group than in the No-CMR group. [31] Our hypothesis is that dominant recovery of effector T cells after auto-PBSCT will contribute to long-term relapse-free survival in Ph + ALL patients.
This study can provide a foundation of auto-PBSCT for Ph + ALL. MRD-based strategies would identify patients who could achieve long-term remission without allo-HCT and lead to safer treatment for Ph + ALL. 
